Destabilization of peptide: MHC interaction induces IL-2 resistant anergy in diabetogenic T cells

Journal of Autoimmunity

Volumn 44, Issue , 2013, Pages 82-90

  Edwards, Lindsay J ^a,b   Evavold, Brian D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

I Ag7; Signaling; T cell anergy; Type 1 diabetes

Indexed keywords

INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT5 PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIVISION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETOGENESIS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STABILITY; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WILD TYPE;

EID: 84881375970     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.07.002     Document Type: Article

References (74)

1. Elias D., Meilin A., Ablamunits V., Birk O.S., Carmi P., Konen-Waisman S., et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 1997, 46:758-764.
2. Tian J., Atkinson M.A., Clare-Salzler M., Herschenfeld A., Forsthuber T., Lehmann P.V., et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. JExp Med 1996, 183:1561-1567.
3. Tisch R., Wang B., Serreze D.V. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. JImmunol 1999, 163:1178-1187.
4. von Herrath M.G., Coon B., Wolfe T., Chatenoud L. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. JImmunol 2002, 168:933-941.
5. Herold K.C., Burton J.B., Francois F., Poumian-Ruiz E., Glandt M., Bluestone J.A. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). JClin Invest 2003, 111:409-418.
6. Pop S.M., Wong C.P., He Q., Wang Y., Wallet M.A., Goudy K.S., et al. The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice. Diabetes 2007, 56:1395-1402.
7. You S., Leforban B., Garcia C., Bach J.F., Bluestone J.A., Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A 2007, 104:6335-6340.
8. Pedotti R., Sanna M., Tsai M., DeVoss J., Steinman L., McDevitt H., et al. Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus. BMC Immunol 2003, 4:2.
9. Overbergh L., Decallonne B., Branisteanu D.D., Valckx D., Kasran A., Bouillon R., et al. Acute shock induced by antigen vaccination in NOD mice. Diabetes 2003, 52:335-341.
10. Liu E., Moriyama H., Abiru N., Miao D., Yu L., Taylor R.M., et al. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. JClin Invest 2002, 110:1021-1027.
11. Pedotti R., Mitchell D., Wedemeyer J., Karpuj M., Chabas D., Hattab E.M., et al. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol 2001, 2:216-222.
12. Margot C.D., Ford M.L., Evavold B.D. Amelioration of established experimental autoimmune encephalomyelitis by an MHC anchor-substituted variant of proteolipid protein 139-151. JImmunol 2005, 174:3352-3358.
13. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6:1167-1175.
14. Wicker L.S., Todd J.A., Peterson L.B. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 1995, 13:179-200.
15. McDevitt H., Singer S., Tisch R. The role of MHC class II genes in susceptibility and resistance to type I diabetes mellitus in the NOD mouse. Horm Metab Res 1996, 28:287-288.
16. Tisch R., McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996, 85:291-297.
17. Todd J.A., Bell J.I., McDevitt H.O. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987, 329:599-604.
18. Stratmann T., Apostolopoulos V., Mallet-Designe V., Corper A.L., Scott C.A., Wilson I.A., et al. The I-Ag7 MHC class II molecule linked to murine diabetes is a promiscuous peptide binder. JImmunol 2000, 165:3214-3225.
19. Carrasco-Marin E., Shimizu J., Kanagawa O., Unanue E.R. The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders. JImmunol 1996, 156:450-458.
20. Harrison L.C., Honeyman M.C., Trembleau S., Gregori S., Gallazzi F., Augstein P., et al. Apeptide-binding motif for I-A(g7), the class II major histocompatibility complex (MHC) molecule of NOD and Biozzi AB/H mice. JExp Med 1997, 185:1013-1021.
21. Yoshida K., Corper A.L., Herro R., Jabri B., Wilson I.A., Teyton L. The diabetogenic mouse MHC class II molecule I-Ag7 is endowed with a switch that modulates TCR affinity. J Clin Invest 2010, 120:1578-1590.
22. Chang K.Y., Suri A., Unanue E.R. Predicting peptides bound to I-Ag7 class II histocompatibility molecules using a novel expectation-maximization alignment algorithm. Proteomics 2007, 7:367-377.
23. Ford M.L., Evavold B.D. Regulation of polyclonal T cell responses by an MHC anchor-substituted variant of myelin oligodendrocyte glycoprotein 35-55. JImmunol 2003, 171:1247-1254.
24. Lamb J.R., Skidmore B.J., Green N., Chiller J.M., Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. JExp Med 1983, 157:1434-1447.
25. Katz J.D., Wang B., Haskins K., Benoist C., Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993, 74:1089-1100.
26. Haskins K., McDuffie M. Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science 1990, 249:1433-1436.
27. Bergman B., Haskins K. Islet-specific T-cell clones from the NOD mouse respond to beta-granule antigen. Diabetes 1994, 43:197-203.
28. Judkowski V., Pinilla C., Schroder K., Tucker L., Sarvetnick N., Wilson D.B. Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. JImmunol 2001, 166:908-917.
29. Stratmann T., Martin-Orozco N., Mallet-Designe V., Poirot L., McGavern D., Losyev G., et al. Susceptible MHC alleles, not background genes, select an autoimmune T cell reactivity. J Clin Invest 2003, 112:902-914.
30. Kasson P.M., Rabinowitz J.D., Schmitt L., Davis M.M., McConnell H.M. Kinetics of peptide binding to the class II MHC protein I-Ek. Biochemistry 2000, 39:1048-1058.
31. McNeil L.K., Evavold B.D. Dissociation of peripheral T cell responses from thymocyte negative selection by weak agonists supports a spare receptor model of T cell activation. Proc Natl Acad Sci U S A 2002, 99:4520-4525.
32. Levisetti M.G., Suri A., Petzold S.J., Unanue E.R. The insulin-specific T cells of nonobese diabetic mice recognize a weak MHC-binding segment in more than one form. JImmunol 2007, 178:6051-6057.
33. Yoshida K., Martin T., Yamamoto K., Dobbs C., Munz C., Kamikawaji N., et al. Evidence for shared recognition of a peptide ligand by a diverse panel of non-obese diabetic mice-derived, islet-specific, diabetogenic T cell clones. Int Immunol 2002, 14:1439-1447.
34. Rosette C., Werlen G., Daniels M.A., Holman P.O., Alam S.M., Travers P.J., et al. The impact of duration versus extent of TCR occupancy on T cell activation: a revision of the kinetic proofreading model. Immunity 2001, 15:59-70.
35. Rosenthal K.M., Edwards L.J., Sabatino J.J., Hood J.D., Wasserman H.A., Zhu C., et al. Low 2-dimensional CD4 T cell receptor affinity for myelin sets in motion delayed response kinetics. PLoS One 2012, 7:e32562.
36. Dittel B.N., Stefanova I., Germain R.N., Janeway C.A. Cross-antagonism of a T cell clone expressing two distinct T cell receptors. Immunity 1999, 11:289-298.
37. Kilgore N.E., Carter J.D., Lorenz U., Evavold B.D. Cutting edge: dependence of TCR antagonism on Src homology 2 domain-containing protein tyrosine phosphatase activity. JImmunol 2003, 170:4891-4895.
38. Wasserman H.A., Beal C.D., Zhang Y., Jiang N., Zhu C., Evavold B.D. MHC variant peptide-mediated anergy of encephalitogenic T cells requires SHP-1. JImmunol 2008, 181:6843-6849.
39. Beverly B., Kang S.M., Lenardo M.J., Schwartz R.H. Reversal of invitro T cell clonal anergy by IL-2 stimulation. Int Immunol 1992, 4:661-671.
40. Rochman Y., Spolski R., Leonard W.J. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009, 9:480-490.
41. Lanzavecchia A., Reid P.A., Watts C. Irreversible association of peptides with class II MHC molecules in living cells. Nature 1992, 357:249-252.
42. Stern L.J., Wiley D.C. The human class II MHC protein HLA-DR1 assembles as empty alpha beta heterodimers in the absence of antigenic peptide. Cell 1992, 68:465-477.
43. Nelson C.A., Petzold S.J., Unanue E.R. Peptides determine the lifespan of MHC class II molecules in the antigen-presenting cell. Nature 1994, 371:250-252.
44. Weber D.A., Evavold B.D., Jensen P.E. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 1996, 274:618-620.
45. Kwok W.W., Reijonen H., Falk B.A., Koelle D.M., Nepom G.T. Peptide binding affinity and pH variation establish functional thresholds for activation of HLA-DQ-restricted T cell recognition. Hum Immunol 1999, 60:619-626.
46. McFarland B.J., Sant A.J., Lybrand T.P., Beeson C. Ovalbumin (323-339) peptide binds to the major histocompatibility complex class II I-A(d) protein using two functionally distinct registers. Biochemistry 1999, 38:16663-16670.
47. Yu B., Gauthier L., Hausmann D.H., Wucherpfennig K.W. Binding of conserved islet peptides by human and murine MHC class II molecules associated with susceptibility to type I diabetes. Eur J Immunol 2000, 30:2497-2506.
48. Lee K.H., Wucherpfennig K.W., Wiley D.C. Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2001, 2:501-507.
49. Hall F.C., Rabinowitz J.D., Busch R., Visconti K.C., Belmares M., Patil N.S., et al. Relationship between kinetic stability and immunogenicity of HLA-DR4/peptide complexes. Eur J Immunol 2002, 32:662-670.
50. Stadinski B.D., Delong T., Reisdorph N., Reisdorph R., Powell R.L., Armstrong M., et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010, 11:225-231.
51. Nikoopour E., Sandrock C., Huszarik K., Krougly O., Lee-Chan E., Masteller E.L., et al. Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. JImmunol 2011, 186:3831-3835.
52. Lori Blanchfield J., Shorter S.K., Evavold B.D. Monitoring the dynamics of T Cell clonal diversity using recombinant peptide:MHC technology. Front Immunol 2013, 4:170.
53. Quill H., Schwartz R.H. Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferation nonresponsiveness. JImmunol 1987, 138:3704-3712.
54. Jenkins M.K., Schwartz R.H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness invitro and invivo. JExp Med 1987, 165:302-319.
55. Jenkins M.K., Chen C., Jung G., Mueller D.L., Schwartz R.H. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. JImmunol 1990, 144:16-22.
56. Wasserman H.A., Evavold B.D. Induction of anergy by antibody blockade of TCR in myelin oligodendrocyte glycoprotein-specific cells. JImmunol 2008, 180:7259-7264.
57. Korb L.C., Mirshahidi S., Ramyar K., Akha A.A.S., Sadegh-Nasseri S. Induction of T Cell anergy by low numbers of agonist ligands. JImmunol 1999, 163:6401-6409.
58. Sloan-Lancaster J., Evavold B.D., Allen P.M. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993, 363:156-159.
59. Fife B.T., Guleria I., Gubbels Bupp M., Eagar T.N., Tang Q., Bour-Jordan H., et al. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. JExp Med 2006, 203:2737-2747.
60. Ryan K.R., Evavold B.D. Persistence of peptide-induced CD4+ T cell anergy invitro. JExp Med 1998, 187:89-96.
61. + helper T cells. JImmunol 1996, 156:1764-1771.
62. Fields P.E., Gajewski T.F., Fitch F.W. Blocked Ras activation in anergic CD4+ T cells. Science 1996, 271:1276-1278.
63. Sloan-Lancaster J., Shaw A.S., Rothbard J.B., Allen P.M. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell 1994, 79:913-922.
64. Gaffen S.L. Signaling domains of the interleukin 2 receptor. Cytokine 2001, 14:63-77.
65. Grundstrom S., Dohlsten M., Sundstedt A. IL-2 unresponsiveness in anergic CD4+ T cells is due to defective signaling through the common gamma-chain of the IL-2 receptor. JImmunol 2000, 164:1175-1184.
66. Migone T.S., Cacalano N.A., Taylor N., Yi T., Waldmann T.A., Johnston J.A. Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. Proc Natl Acad Sci U S A 1998, 95:3845-3850.
67. Ram P.A., Waxman D.J. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. JBiol Chem 1997, 272:17694-17702.
68. Somani A.K., Bignon J.S., Mills G.B., Siminovitch K.A., Branch D.R. Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphatase. JBiol Chem 1997, 272:21113-21119.
69. Cuevas B., Lu Y., Watt S., Kumar R., Zhang J., Siminovitch K.A., et al. SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. JBiol Chem 1999, 274:27583-27589.
70. Minoo P., Zadeh M.M., Rottapel R., Lebrun J.J., Ali S. Anovel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling. Blood 2004, 103:1398-1407.
71. Xiao W., Hong H., Kawakami Y., Kato Y., Wu D., Yasudo H., et al. Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell 2009, 16:161-171.
72. Oxenius A., Zinkernagel R.M., Hengartner H. Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection. Immunity 1998, 9:449-457.
73. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998, 95:1178-1183.
74. Schnell F.J., Alberts-Grill N., Evavold B.D. CD8+ T cell responses to a viral escape mutant epitope: active suppression via altered SHP-1 activity. JImmunol 2009, 182:1829-1835.